doi: 10.1093/jacamr/dlab051.
eCollection 2021 Jun.
Education: The role of the first siderophore cephalosporin Fetcroja® (cefiderocol) in UK clinical practice: introduction
Affiliations
- PMID: 34223148
- PMCID: PMC8251259
- DOI: 10.1093/jacamr/dlab051
Item in Clipboard
Education: The role of the first siderophore cephalosporin Fetcroja® (cefiderocol) in UK clinical practice: introduction
JAC Antimicrob Resist.
.
Erratum in
-
Erratum to: Education: The role of the first siderophore cephalosporin Fetcroja® (cefiderocol) in UK clinical practice: introduction; Antibiotic resistance during and beyond COVID-19; Education: An introduction to the core data for cefiderocol with reflections for a possible role within UK clinical practice; Education: A compassionate use of cefiderocol to treat osteomyelitis caused by an XDR Pseudomonas aeruginosa; Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection; Education: An overview from the author of 'Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients'.JAC Antimicrob Resist. 2021 Aug 28;3(3):dlab109. doi: 10.1093/jacamr/dlab109. eCollection 2021 Sep. JAC Antimicrob Resist. 2021. PMID: 34466802 Free PMC article.
-
Erratum to: Education: The role of the first siderophore cephalosporin Fetcroja® (cefiderocol) in UK clinical practice: introduction; Education: An introduction to the core data for cefiderocol with reflections for a possible role within UK clinical practice; Education: A compassionate use of cefiderocol to treat osteomyelitis caused by an XDR Pseudomonas aeruginosa; Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection; Education: An overview from the author of 'Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients'.JAC Antimicrob Resist. 2021 Aug 28;3(3):dlab110. doi: 10.1093/jacamr/dlab110. eCollection 2021 Sep. JAC Antimicrob Resist. 2021. PMID: 34466803 Free PMC article.
Abstract
Welcome to this special JAC-Antimicrobial Resistance Supplement, which is sponsored by Shionogi BV. The march of increasing Gram-negative resistance is relentless, and in the last 10 years we have seen a development in the pipeline of antimicrobials targeting the most resistant Gram-negative bacteria. Within this Supplement, we will present the current landscape for Gram-negative treatments, the launch data for cefiderocol, UK potential positioning and examples of early use.
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
References
-
- PHE. English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR): Report 2019 to 2020. https://assets.publishing.service.gov.uk/government/uploads/system/uploa....
-
- Nordmann P, Gniadkowski M, Giske CG. et al.Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 2012; 18: 432–8. - PubMed
-
- PHE. AMR Local Indicators. https://fingertips.phe.org.uk/profile/amr-local-indicators.
-
- Shionogi BV. Fetcroja (cefiderocol). Summary of Product Characteristics. 2020.
LinkOut - more resources
Full Text Sources